Navigation Links
OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
Date:2/11/2010

HONG KONG, Feb. 11 /PRNewswire/ -- OrbusNeich today announced that the first patient has been enrolled in a randomized clinical trial of the Genous Bio-engineered R stent in China.

A multicenter, randomized, controlled study, the trial will enroll 180 patients split evenly between the control and test arms at 11 sites countrywide. The primary study objective is to demonstrate the safety and effectiveness of the Genous Bio-engineered R stent compared to the Medtronic Endeavor Sprint stent.  

The study population will consist of patients ages 18 to 75 with symptoms of angina or myocardial ischemia. The primary endpoints are difference in Major Adverse Cardiac Event (MACE) rates between the two groups at 12 months following implant and 270 day angiographic Late Loss (LL). Secondary endpoints include all-cause and cardiac mortality, myocardial infarction, in-stent thrombosis, MACE rates at 30, 60, 90, 180 and 270 days, as well as clinically driven Target Lesion Revascularization (TLR), Target Vessel Revascularization (TVR) and Target Lesion Failure (TLF) rates at 30, 60, 90, 180, 270 and 360 days.  

The first patient was enrolled in the study at Beijing Chaoyang Hospital on December 8, 2009.

"We believe that the Genous Bio-engineered R stent will provide an excellent treatment option to patients who present challenging cases with standard drug eluting stents," said Prof. Lu Shuzheng from Anzhen Hospital, principal investigator of the trial.

Al Novak, OrbusNeich's chairman and CEO, added, "We are excited to take the Genous Bio-engineered R stent into this pivotal trial in China. We expect that clinical data from this study will show positive benefits for patients, including those who
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
2. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
5. Clinical Impact of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
6. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
7. Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
8. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
9. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008
10. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
11. Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Governor Tom Wolf announced today that ... markets implants in the spine and trauma markets, will establish ... Northampton County to serve as its ... 25 new, full-time jobs. "Tyber Medical,s decision ... more than two dozen, high-paying jobs is great news for ...
(Date:8/4/2015)... 2015 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... and Chief Executive Officer, Doug Godshall , is ... Growth Conference at 8:30 a.m. EDT on Thursday, August ... 2015 at the InterContinental Boston. A live ...
(Date:8/4/2015)... -- The Pittsburgh Life Sciences Greenhouse (PLSG), the region,s only ... of its portfolio companies, Medrobotics Corporation, has received FDA ... System in the U.S.  "I couldn,t ... John W. Manzetti , president and CEO of ... spinning out of The Robotics Institute at Carnegie Mellon ...
Breaking Medicine Technology:Wolf Administration Announces Tyber Medical to Establish Operations and Create New Jobs in Northampton County 2Wolf Administration Announces Tyber Medical to Establish Operations and Create New Jobs in Northampton County 3HeartWare Presentation At The Canaccord Genuity 35th Annual Growth Conference To Be Webcast 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 3
... and NEW YORK, Nov. 9, 2010 ... ACCP ), a biopharmaceutical company leveraging its proprietary drug-delivery ... care and diabetes, announced today that its Chairman, Steven Rouhandeh, ... Investors Conference on Friday, November 12, 2010, at 1:00 pm ...
... Nov. 9, 2010 MonoSol Rx, the ... delivery company specializing in proprietary pharmaceutical film products, today ... 7,824,588 from the United States Patent and Trademark Office ... intellectual property protection for the Company,s film products and ...
Cached Medicine Technology:Access Pharmaceuticals to Present at LifeTech Capital Miami Medical Investors Conference on November 12th 2MonoSol Rx Issued Strategic U.S. Patent Governing the Manufacturing of Pharmaceutical Films 2MonoSol Rx Issued Strategic U.S. Patent Governing the Manufacturing of Pharmaceutical Films 3
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... information, checking with “Dr. Google” before calling a physician. In an effort to ... the first health care provider in Pennsylvania to publicly share patient satisfaction ratings ...
(Date:8/4/2015)... ... 04, 2015 , ... NutraScience Labs , a world-class ... joined over 200 other Long Island-based corporations as participants in the 10th annual ... Jones Beach State Park in Wantagh, New York. , According to Mindy Davidson, ...
(Date:8/4/2015)... ... August 04, 2015 , ... Patients are ... offered by the world renowned Beverly Hills facelift surgeon , Dr. Paul ... surgery techniques helps individuals to achieve an outer appearance that meets their personal ...
(Date:8/4/2015)... ... August 04, 2015 , ... Montclair State University and Atlantic Health ... of its kind in New Jersey, which starting this Fall will help prepare those ... School partnered with Atlantic Health System, one of the largest health care organizations in ...
(Date:8/4/2015)... ... August 04, 2015 , ... Providigm, LLC, a developer of ... announced details of the Advanced level of their national accreditation for Quality Assurance ... Accreditation program , introduced in 2013, is based on standards for excellence in ...
Breaking Medicine News(10 mins):Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 3Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 3Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3
... as sprain or muscle rupture raised venous thrombosis odds, study ... injures -- including ankle sprains and muscle ruptures -- ... or lungs, suggests a study by researchers in the Netherlands. ... treatments such as surgery, a plaster cast, and extended bed ...
... of the largest studies yet of Alzheimers disease ... researchers at Mayo Clinic Jacksonville have found strong ... risk factor APOE4 influence who is at risk ... , Studying 25 multigenerational families of individuals diagnosed ...
... a human-pathogenic virus which belongs to the herpes virus ... infestation rate of more than 90 %, EBV is ... genome consists of double-stranded DNA, and it is one ... humans under certain circumstances. EBV-associated cancers include lymphomas (cancer ...
... are sometimes unable to carry out their relatives wish to ... making a gift of life and protecting the body of ... Advanced Nursing. , Researchers from the University of Southampton, UK, ... their relatives bodies be used for organ donations about their ...
... the increase , , THURSDAY, Jan. 17 (HealthDay News) -- ... in three decades, according to a new report released ... Rachel Jones, senior research associate at the Guttmacher Institute, ... findings will be published in the March issue of ...
... ... - Multi-year collaboration for NLP-based literature search and ... Linguamatics,Ltd, the leader in natural language processing (NLP) for life ... an affiliate of the Medical Knowledge Group (MKG), announce a,multi-year ...
Cached Medicine News:Health News:Minor Leg Injuries Might Boost Blood Clot Risk 2Health News:Evidence found for genes that affect risk of developing Alzheimer's disease 2Health News:Evidence found for genes that affect risk of developing Alzheimer's disease 3Health News:Evidence found for genes that affect risk of developing Alzheimer's disease 4Health News:A tricky tumor virus 2Health News:Relatives who decline organ donations face conflict and guilt 2Health News:Relatives who decline organ donations face conflict and guilt 3Health News:U.S. Abortion Rate Falls to Lowest Level in Decades 2Health News:U.S. Abortion Rate Falls to Lowest Level in Decades 3Health News:Linguamatics and 81qd Sign Multi-Year Collaboration in Knowledge Discovery for Product Life Cycle Management 2Health News:Linguamatics and 81qd Sign Multi-Year Collaboration in Knowledge Discovery for Product Life Cycle Management 3Health News:Linguamatics and 81qd Sign Multi-Year Collaboration in Knowledge Discovery for Product Life Cycle Management 4
... Healon is a sterile, nonpyrogenic, viscoelastic ... high molecular weight fraction of sodium ... sodium hyaluronate dissolved in physiological sodium ... high molecular weight polymer is made ...
... fiscal year 2004, Biomet plans to ... to the global market, enhancing visualization ... Acumen technology was developed in conjunction ... based in Hollywood, Florida. Procedure-specific software ...
... response and eye movement is an important ... because eye movements and pupil responses are ... visual neuronal centers and pathways that are ... Analyzer (VPA) provides pre-programmed visual stimuli and ...
From the initial viewing screen through the completion of the exam the ADIS-9000 has been designed for ease of use and intuitive operation. The built-in software simplifies patient reporting, image s...
Medicine Products: